» Articles » PMID: 35448032

Immune Landscape in PTEN-Related Glioma Microenvironment: A Bioinformatic Analysis

Overview
Journal Brain Sci
Publisher MDPI
Date 2022 Apr 21
PMID 35448032
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: PTEN gene mutations are frequently found in the genetic landscape of high-grade gliomas since they influence cell proliferation, proangiogenetic pathways, and antitumoral immune response. The present bioinformatics analysis explores the PTEN gene expression profile in HGGs as a prognostic factor for survival, especially focusing on the related immune microenvironment. The effects of PTEN mutation on the susceptibility to conventional chemotherapy were also investigated. Methods: Clinical and genetic data of GBMs and normal tissue samples were acquired from The Cancer Genome Atlas (TCGA)-GBM and Genotype-Tissue Expression (GTEx) online databases, respectively. The genetic differential expressions were analyzed in both groups via the one-way ANOVA test. Kaplan−Meier survival curves were applied to estimate the overall survival (OS) and disease-free survival (DFS). The Genomics of Drug Sensitivity in Cancer platform was chosen to assess the response of PTEN-mutated GBMs to temozolomide (TMZ). p < 0.05 was fixed as statistically significant. On Tumor Immune Estimation Resource and Gene Expression Profiling Interactive Analysis databases, the linkage between immune cell recruitment and PTEN status was assessed through Spearman’s correlation analysis. Results: PTEN was found mutated in 22.2% of the 617 TCGA-GBMs patients, with a higher log2-transcriptome per million reads compared to the GTEx group (255 samples). Survival curves revealed a worse OS and DFS, albeit not significant, for the high-PTEN profile GBMs. Spearman’s analysis of immune cells demonstrated a strong positive correlation between the PTEN status and infiltration of Treg (ρ = 0.179) and M2 macrophages (ρ = 0.303). The half-maximal inhibitor concentration of TMZ was proven to be lower for PTEN-mutated GBMs compared with PTEN wild-types. Conclusions: PTEN gene mutations prevail in GBMs and are strongly related to poor prognosis and least survival. The infiltrating immune lymphocytes Treg and M2 macrophages populate the glioma microenvironment and control the mechanisms of tumor progression, immune escape, and sensitivity to standard chemotherapy. Broader studies are required to confirm these findings and turn them into new therapeutic perspectives.

Citing Articles

Research progress on the role of PTEN deletion or mutation in the immune microenvironment of glioblastoma.

Du L, Zhang Q, Li Y, Li T, Deng Q, Jia Y Front Oncol. 2024; 14:1409519.

PMID: 39206155 PMC: 11349564. DOI: 10.3389/fonc.2024.1409519.


Immunohistochemical Expression of PTEN in Canine Gliomas.

Molin J, Jose-Lopez R, Ramirez G, Pumarola M Animals (Basel). 2024; 14(14).

PMID: 39061577 PMC: 11273977. DOI: 10.3390/ani14142115.


Investigating the effects of PTEN mutations on cGAS-STING pathway in glioblastoma tumours.

Dogan E, Yildirim Z, Akalin T, Ozgiray E, Akinturk N, Aktan C J Neurooncol. 2024; 166(2):283-292.

PMID: 38214828 PMC: 10834568. DOI: 10.1007/s11060-023-04556-4.


Investigating the Association between the Autophagy Markers LC3B, , and DRAM and Autophagy-Related Genes in Glioma.

Danish F, Qureshi M, Mirza T, Amin W, Sufiyan S, Naeem S Int J Mol Sci. 2024; 25(1).

PMID: 38203743 PMC: 10779014. DOI: 10.3390/ijms25010572.


Non-Association of Driver Alterations in PTEN with Differential Gene Expression and Gene Methylation in IDH1 Wildtype Glioblastomas.

Mallik M, Majumdar K, Mujtaba S Brain Sci. 2023; 13(2).

PMID: 36831729 PMC: 9953940. DOI: 10.3390/brainsci13020186.


References
1.
Qin Z, Zhang X, Chen Z, Liu N . Establishment and validation of an immune-based prognostic score model in glioblastoma. Int Immunopharmacol. 2020; 85:106636. DOI: 10.1016/j.intimp.2020.106636. View

2.
Gajewski T . Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res. 2006; 12(7 Pt 2):2326s-2330s. DOI: 10.1158/1078-0432.CCR-05-2517. View

3.
Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

4.
Eagan R, Scott M . Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol. 1983; 1(1):38-44. DOI: 10.1200/JCO.1983.1.1.38. View

5.
Ming M, He Y . PTEN in DNA damage repair. Cancer Lett. 2012; 319(2):125-129. PMC: 3326178. DOI: 10.1016/j.canlet.2012.01.003. View